Mammary Cell News Volume 13.24 | Jun 24, 2021

    0
    68







    2021-06-24 | MCN 13.24


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.24 – 24 June, 2021
    TOP STORY

    Clonal Fitness Inferred from Time-Series Modelling of Single-Cell Cancer Genomes

    Researchers generated 42,000 genomes from multi-year time-series single-cell whole-genome sequencing of breast epithelium and primary TNBC patient-derived xenografts, revealing the nature of copy number alteration-defined clonal fitness dynamics induced by TP53 mutation and cisplatin chemotherapy.
    [Nature]

    AbstractPress Release

    Survey results on the insights and hurdles of CRISPR genome editing.
    PUBLICATIONSRanked by the impact factor of the journal

    Interaction between HLA-G and NK Cell Receptor KIR2DL4 Orchestrates HER2-Positive Breast Cancer Resistance to Trastuzumab

    Investigators found that the nonclassical histocompatibility antigen HLA-G desensitized breast cancer cells to trastuzumab by binding to the natural killer cell receptor KIR2DL4.
    [Signal Transduction and Targeted Therapy]

    Full Article

    Highly Metastatic Claudin-Low Mammary Cancers Can Originate from Luminal Epithelial Cells

    The authors showed that persistent oncogenic RAS signaling caused highly metastatic triple-negative mammary tumors in mice. The continuous signaling of oncogenic RAS played a crucial role in the cellular plasticity and maintenance of the mesenchymal and stem cell characteristics of claudin-low mammary cancer cells.
    [Nature Communications]

    Full Article

    Immune Checkpoint Blockade Reprograms Systemic Immune Landscape and Tumor Microenvironment in Obesity-Associated Breast Cancer

    In lean and obese mice, tumor progression and immune reprogramming were quantified in breast cancer tumors treated with anti-programmed death-1 (PD-1) or control. Scientists found anti-PD-1 to be highly efficacious in obese mice by reinvigorating durable antitumor immunity.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Msi1 Promotes Breast Cancer Metastasis by Regulating Invadopodia-Mediated Extracellular Matrix Degradation via the Timp3–Mmp9 Pathway

    Researchers found that the RNA-binding protein Musashi1 (Msi1) exhibited elevated expression in invasive breast tumors and promoted lung metastasis of mammary cancer cells. Suppression of Msi1 reduced invadopodia formation in mammary cancer cells.
    [Oncogene]

    Abstract

    Necroptotic Virotherapy of Oncolytic Alphavirus M1 Cooperated with Doxorubicin Displays Promising Therapeutic Efficacy in TNBC

    Investigators found that Doxorubicin enhanced the oncolytic effect of the M1 virus by up to 100-fold specifically in TNBC in vitro, and significantly stalled the tumor growth of TNBC in vivo, through promoting intratumoral virus replication and further triggering apoptosis in addition to necroptosis.
    [Oncogene]

    Abstract

    TSHZ2 Is an EGF-Regulated Tumor Suppressor That Binds to the Cytokinesis Regulator PRC1 and Inhibits Metastasis

    Scientists identified delayed down-regulated genes (DDGs) in mammary cells after prolonged treatment with epidermal growth factor (EGF). The expression of these DDGs was low in mammary tumors and correlated with prognosis.
    [Science Signaling]

    Abstract

    Long Noncoding RNA AFAP1-AS1 Promotes Tumor Progression and Invasion by Regulating the miR-2110/Sp1 Axis in Triple-Negative Breast Cancer

    The authors used Cell Counting Kit-8, colony formation, wound healing migration, Transwell invasion, and nude mouse xenograft assays to confirm the role of the long noncoding RNA actin filament-associated protein 1 antisense RNA1 (AFAP1-AS1) in the proliferation, migration of TNBC cells in vitro and in vivo.
    [Cell Death & Disease]

    Full Article

    Establishment and Characterization of Immortalized Human Breast Cancer Cell Lines from Breast Cancer Patient-Derived Xenografts (PDX)

    Researchers utilized breast cancer patient-derived xenografts from the Mayo Breast Cancer Genome Guided Therapy Study to establish two immortalized, genomically unique breast cancer cell lines.
    [npj Breast Cancer]

    Full Article

    Glutathione Peroxidase-1 Regulates ASK1-Dependent Apoptosis via Interaction with TRAF2 in RIPK3-Negative Cancer Cells

    Scientists showed that GPx type 1 (GPx1) played a key regulatory role in the apoptosis signaling pathway. The absence of GPx1 augmented TNF-α-induced apoptosis in various RIPK3-negative cancer cells by markedly elevating the level of cytosolic H2O2, which was derived from mitochondria.
    [Experimental & Molecular Medicine]

    Full Article

    Apoptosis-Inducing Anti-HER2 Agents Operate through Oligomerization-Induced Receptor Immobilization

    The authors investigated how the spatiotemporal receptor organization at the cell surface was modulated by biparatopic designed ankyrin repeat proteins (bipDARPins), which potently induced apoptosis in human epidermal growth factor receptor 2-addicted breast cancer cell lines.
    [Communications Biology]

    Full Article

    Combination of 131I-Trastuzumab and Lanatoside C Enhanced Therapeutic Efficacy in HER2 Positive Tumor Model

    Researchers investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal growth factor receptor 2 (HER2) positive tumor progression in NCI-N87 xenograft model.
    [Scientific Reports]

    Full Article

    Virtual Conference Exhibition: Organoids
    REVIEWS

    Estrogen Receptor-α Signaling in Post-Natal Mammary Development and Breast Cancers

    The authors describe the cellular and molecular features of the luminal cell lineage expressing estrogen receptor-α (ERα) and provide an overview of the transgenic mouse models impacting ERα signaling, highlighting the pivotal role of ERα in mammary gland morphogenesis and function and its implication in the tumorigenic processes.
    [Cellular and Molecular Life Sciences]

    Full Article

    Breast Cancer Immunotherapy: Current and Novel Approaches

    Personalized immunotherapy has recently been proposed as a potential complementary medicine with immunotherapy and chemotherapy for overcoming breast cancer (BC). Investigators discuss the brief association of these methods and future directions in BC immunotherapy.
    [International Immunopharmacology]

    Abstract

    INDUSTRY AND POLICY NEWS

    FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 T-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer

    ImmunityBio, Inc. announced it has received FDA authorization to conduct a Phase Ib/II open-label study to evaluate the safety and preliminary efficacy of its superagonist Anktiva and PD-L1 targeted high-affinity natural killer (t-haNK) cells in combination with standard chemo and Trodelvy, in subjects with advanced TNBC.
    [ImmunityBio, Inc.]

    Press Release

    FEATURED EVENT

    2021 Annual Meeting of Korean Society for Stem Cell Research (KSSCR)

    August 12 – 14, 2021
    Busan, South Korea

    > See All Events

    JOB OPPORTUNITIES

    Research Fellow – Molecular Pharmacology & Experimental Therapeutics

    Mayo Clinic Health System – Rochester, Minnesota, United States

    Postdoctoral Research Fellow – Breast Cancer

    University of Michigan – Ann Arbor, Michigan, United States

    Director – Medical Affairs Oncology

    Gilead Sciences, Inc. – Foster City, California, United States

    Postdoctoral Fellow – Translational Cancer Research

    Icahn School of Medicine at Mount Sinai – New York City, New York, United States

    Postdoctoral Associate – Breast Cancer Hormone Therapy Resistance

    Baylor College of Medicine – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter